• PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced topline data from its Phase 2b trial of bentracimab in healthy, older volunteers 50-80 years old.

• The trial in 150 subjects receiving bentracimab and 50 subjects receiving placebo after all were pretreated with dual antiplatelet therapy composed of AstraZeneca Plc's (NASDAQ: AZN) Brilinta (ticagrelor) and low-dose aspirin.

• Bentracimab is a recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations.

• The Phase 2b trial achieved its primary endpoint of reversing ticagrelor's inhibition of platelet function in actively treated subjects versus placebo.

• Bentracimab is currently being evaluated in the REVERSE-IT Phase 3 trial in approximately 200 participants.

• A prespecified interim analysis from the REVERSE-IT trial will be presented on November 15 at the American Heart Association's Scientific Sessions 2021.

• PhaseBio is targeting marketing application submission to the FDA in mid-2022.

• Also Read: CytoSorbents To Start US Study With CytoSorb For Ticagrelor Removal.

• Price Action: PHAS shares are down 3.21% at $3.92 during the market session on the last check Wednesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Amneal Posts Mixed Bag Q3 Earnings; Acquires Puniska To Bolster Injectable Business

• CVS Health Q3 Earnings Helped By COVID-19 Vaccinations; Raises FY21 Earnings Outlook

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.